Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Tuberous Sclerosis 3Seizures 3Sturge-Weber Syndrome 2Nausea 2Vomiting 1Parasomnias 1Pain 1Neoplasms 1Marijuana Abuse 1Dysgeusia 1Drug Resistant Epilepsy 1Cognitive Dysfunction 1Chemotherapy-Induced Peripheral Neuropathy 1Cancer Pain 1Cachexia 1Breast Neoplasms 1Behavior 1Arthralgia 1Appetitive Behavior 1Anxiety Disorders 1

Interventions

Trastuzumab 350Paclitaxel 334Cyclophosphamide 315Docetaxel 291Capecitabine 181Doxorubicin 180Letrozole 165Tamoxifen 145Bevacizumab 124Fulvestrant 118Carboplatin 118exemestane 111Lapatinib 111Anastrozole 111Radiotherapy 105Epirubicin 104Gemcitabine 97palbociclib 83Exercise 78Vinorelbine 77Fluorouracil 77Surveys and Questionnaires 71pertuzumab 67Filgrastim 64Albumin-Bound Paclitaxel 64eribulin 55Magnetic Resonance Spectroscopy 55Everolimus 52Blood Specimen Collection 51Zoledronic Acid 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms × Cannabidiol × Clear all
NCT04754399 2025-05-09

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

University of Michigan Rogel Cancer Center

Phase 2 Completed
40 enrolled 10 charts
Breast

Breast Neoplasms, Arthralgia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡